PGF and preeclampsia: However, in Caillon’s study, the sFlt-1/PlGF ratio value was still significantly higher among patients with later preeclampsia compared to the control, for whom mean values were 32 ± 25, providing proof that sFlt-1/PlGF is a reliable marker of screening in a population of high-risk patients, where it can be used to accurately distinguish high-risk patients who need intensive monitoring from high-risk patients for whom hospitalization was not required, despite having a risk factor.